First Citizens Bank & Trust Co. Has $1 Million Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• First Citizens Bank & Trust Co. increased its stake in Jazz Pharmaceuticals PLC by 268.1% during the second quarter, holding shares worth approximately $1 million.
• Several institutional investors, including Dimensional Fund Advisors and JPMorgan Chase, have recently boosted their investments in Jazz Pharmaceuticals, with institutional investors now owning 89.14% of the company's stock.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Jazz Pharmaceuticals, with target prices generally ranging around $180.00.

First Citizens Bank & Trust Co. lifted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 268.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,426 shares of the specialty pharmaceutical company's stock after purchasing an additional 6,865 shares during the quarter. First Citizens Bank & Trust Co.'s holdings in Jazz Pharmaceuticals were worth $1,000,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Dimensional Fund Advisors LP increased its stake in shares of Jazz Pharmaceuticals by 14.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after purchasing an additional 293,360 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Jazz Pharmaceuticals by 4.7% during the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company's stock worth $206,343,000 after purchasing an additional 74,501 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after purchasing an additional 391,660 shares during the last quarter. Swedbank AB boosted its holdings in shares of Jazz Pharmaceuticals by 10.0% during the 1st quarter. Swedbank AB now owns 1,102,143 shares of the specialty pharmaceutical company's stock worth $136,831,000 after buying an additional 100,211 shares during the period. Finally, Perpetual Ltd boosted its holdings in shares of Jazz Pharmaceuticals by 60.2% during the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after buying an additional 357,784 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price objective for the company. Zacks Research raised shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. The Goldman Sachs Group upped their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a report on Friday, August 29th. Wells Fargo & Company set a $170.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday. Finally, Royal Bank Of Canada upped their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $180.00.

Insiders Place Their Bets

In other news, Director Bruce C. Cozadd sold 3,500 shares of the firm's stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $140.00, for a total transaction of $490,000.00. Following the completion of the transaction, the director directly owned 408,826 shares of the company's stock, valued at approximately $57,235,640. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 11,500 shares of company stock valued at $1,525,280. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $138.53 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The firm has a fifty day moving average price of $130.44 and a two-hundred day moving average price of $116.90. The company has a market cap of $8.40 billion, a PE ratio of -20.58, a price-to-earnings-growth ratio of 8.21 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period last year, the company earned $5.30 earnings per share. Jazz Pharmaceuticals's revenue for the quarter was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.